---
title: Innovation Labs to Enhance Collaboration
nct_id: NCT05395286
overall_status: COMPLETED
phase: NA
sponsor: State University of New York at Buffalo
study_type: INTERVENTIONAL
primary_condition: Collaboration Attitudes and Behavior
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05395286.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05395286"
ct_last_update_post_date: 2026-04-27
last_seen_at: "2026-05-12T06:18:48.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Innovation Labs to Enhance Collaboration

**Official Title:** Controlled Evaluation of Innovation Labs for Enhancing Collaboration Among Early Career Scholars in the CTSA Network

**NCT ID:** [NCT05395286](https://clinicaltrials.gov/study/NCT05395286)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 94
- **Lead Sponsor:** State University of New York at Buffalo
- **Collaborators:** National Center for Advancing Translational Sciences (NCATS)
- **Conditions:** Collaboration Attitudes and Behavior
- **Start Date:** 2017-08-03
- **Completion Date:** 2020-06-25
- **CT.gov Last Update:** 2026-04-27

## Brief Summary

Conduct and evaluate the impact of two week-long Innovation Labs on collaboration attitudes and behavior among early career scholars. Applicants to each Innovation Lab will be screened and then randomized to either the Innovation Lab group or a control group.

## Detailed Description

Building on the science of team science and preliminary work at the Buffalo and Vanderbilt CTSAs, the investigators worked with industry partner Knowinnovation to implement, assess, and disseminate an innovative and promising method for stimulating and nurturing new transdisciplinary research teams across the CTSA Program consortium: Innovation Labs. The study focused on early career investigators. The study took a translational science approach to identify and test "best practices". To accomplish this, the study critically evaluated the impact of Innovation Labs in two preliminary randomized controlled trials (RCTs). In collaboration with NCATs and broad input from the CTSA network, the investigators developed a clinical and translational research grand challenge focus for each Innovation Lab. A diverse applicant pool of early career investigators invited from every CTSA hub in the consortium was reviewed, and top applicants were randomized to a 5-day residential Innovation Lab or "treatment as usual" control group. Measures of process and outcome were collected from the application phase through 12-month follow-up and aggregated across the two RCTs. Given the preliminary nature of the work and an emerging consensus regarding the science of team science, primary outcomes were measures of the depth and breadth of participants collaborative networks and attitudes towards collaboration, which were predicted to be enhanced in the Innovation Lab group compared to the treatment as usual control group. Initial data on the degree to which Innovation Labs resulted in increased transdisciplinary collaborative output were also examined.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Completion of application and baseline assessment.
* Faculty at a NIH CTSA hub institution or regional partner.
* Early stage investigators (NIH-defined as "within 10 years of completing his/her terminal research degree or is within 10 years of completing medical residency (or the equivalent)") who are emerging as independent scholars.
* Ratings of goodness of fit with the topic of the Innovation Lab. Applications were reviewed for the above criteria and ranked by committee according to goodness of fit with the topic of the Innovation Lab, the quality and quantity of academic productivity and collaboration, and contribution to diversity of perspectives among Lab participants (e.g., biomedical and social/psychological, basic and applied). Top-ranked applicants were retained for randomization to the Innovation Lab group or control group.
```

## Arms

- **Innovation Lab Group** (EXPERIMENTAL) — Randomized to attend the Innovation Lab
- **Control Group** (NO_INTERVENTION) — Randomized to NOT attend the Innovation Lab

## Interventions

- **Innovation Lab** (BEHAVIORAL) — An Innovation Lab is a facilitated 5-day residential event designed to create novel, transdisciplinary and potentially transformative research ideas and proposals to address a specific grand challenge. Participants, along with a director, organizers, subject matter guides, and KI facilitators communally explore the problem space, generate a broad range of ideas, and form transdisciplinary teams to pursue research projects.

## Primary Outcomes

- **MATRICx Collaboration Benefits/Motivators Scale** _(time frame: 15 months)_ — Self-report: The Motivation Assessment for Team Readiness, Integration, and Collaboration (MATRICx; Mallinson, Lotrecchiano, et al., 2016) benefits scale includes 17 items that tap into perceived motivators/benefits of collaboration. Each is rated on a 1-4 scale. Scale scores were computed as the mean of all 17 items, for a benefits scale score ranging from 1-4, with higher scores indicating greater collaboration readiness.
- **MATRICx Collaboration Barriers/Threats Scale** _(time frame: 15 months)_ — Self-report: The Motivation Assessment for Team Readiness, Integration, and Collaboration (MATRICx; Mallinson, Lotrecchiano, et al., 2016) Threats Scale includes 31 barriers to -- or threats of -- collaboration. Each is rated on a 1-4 scale. Scale scores were computed as the mean of all 31 items, for a Barriers/Threats scale score ranging from 1-4, with lower scores indicating greater collaboration readiness.
- **Transdisciplinary Orientation Scale** _(time frame: 15 months)_ — Self-report: The Transdisciplinary Orientation scale (TDO; Misra, Stokols, \& Cheng, 2015) is a 12-item scale that measures values, attitudes, and beliefs, and conceptual skills and behaviors, that assesses the degree to which participants are oriented towards transdisciplinary collaboration. Items are rated on a five-point scale (1="Strongly Disagree," 5="Strongly Agree"). The total score is the mean of all 12 items, with a resulting 1-5 range, in which higher scores indicate greater transdisciplinary collaboration orientation.
- **Collaboration Network Size** _(time frame: 36 Months (18-monts pre- and post-treatment, after excluding articles published within +/-3 months of the Innovation Lab))_ — Objective number of collaborators from published articles on PubMed

## Secondary Outcomes

- **Self-Reported Number of Grants Submitted Per Year** _(time frame: 21 months (9 months pre-treatment [obtained at baseline and EOT]; 12 months post-treatment [obtained at 6- and 12-month follow-up]))_
- **ILab Met Goal - New Collab** _(time frame: 12 months (End of Treatment [3 months post-baseline], 6-Month Follow-Up [9 months post-baseline], and 12-Month Follow-Up [15 months post-baseline]))_
- **ILab Met Goal - Novel Proposals** _(time frame: 12 months (End of Treatment [3 months post-baseline], 6-Month Follow-Up [9 months post-baseline], and 12-Month Follow-Up [15 months post-baseline]))_
- **ILab - Recommend** _(time frame: 12 months (End of Treatment [3 months post-baseline], 6-Month Follow-Up [9 months post-baseline], and 12-Month Follow-Up [15 months post-baseline]))_
- **ILab - Positive Impact** _(time frame: 12 months (End of Treatment [3 months post-baseline], 6-Month Follow-Up [9 months post-baseline], and 12-Month Follow-Up [15 months post-baseline]))_

## Locations (1)

- University at Buffalo, Buffalo, New York, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university at buffalo|buffalo|new york|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05395286.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05395286*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*